- Details
- Description
-
Packaging Size30t/bottle
-
Strength80mg
-
CompositonElafibranor
-
Treatmentprimary biliary cholangitis
-
Formtablet
-
BrandElafinor
-
Quantity Unit80mg*30t/box
-
ManufacturerTongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
About Elafibranor
Elafibranor is a medication used for the treatment of primary biliary cholangitis.
Elafibranor is a dual PPARα/δ agonist. Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro.
Primary Biliary Cholangitis
Indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA
80 mg PO qDay
Dosage Modifications
Bile acid sequestrants
- Administer elafibranor ≥4 hr before or ≥4 hr after administering bile acid sequestrant, or at as great an interval as possible
Renal impairment
- Mild, moderate, or severe: No dosage adjustment recommended
Hepatic impairment
- Mild (Child-Pugh A): No dosage adjustment recommended
- Moderate-to-severe (Child-Pugh B or C): Consider discontinuing if patient progresses to moderate or severe hepatic impairment
- Decompensated cirrhosis (eg, ascites, variceal bleeding, hepatic encephalopathy): Safety and efficacy not established; use not recommended
